Novartis boosts bid for Chiron

Swiss pharma company Novartis has raised its bid to purchase Emeryville, CA–based vaccine maker Chiron. In a written statement, Chiron said the new bid was added as an amendment to the existing merger agreement, making the deal now worth roughly $5.4 billion, versus the older offer of $5.1 billion. Novartis already owns a 44% stake in Chiron. Shareholders in Chiron are slated to meet on April 12 to discuss further the takeover. A shareholder vote is scheduled for April 19.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions